Clinical Trial Update: A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital) [EARLY_Phase 1]

View source ↗

Summary

Early-phase study evaluating GC101 tumor-infiltrating lymphocytes (TIL) in patients with recurrent or refractory gastrointestinal tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• GC101 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Gastrointestinal Tumor | EARLY_Phase 1 | Status: RECRUITING